Incomplete Conditional PMA Studies Are Target Of FDA Scrutiny
This article was originally published in The Gray Sheet
Executive Summary
FDA has begun contacting sponsors of approved premarket approval applications with incomplete conditional postmarket studies to assess the status of the investigations.